AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo, meanwhile, already has Phase 3 data on its amylin drug cagrilintide, which was assessed in a trial alone and as part of a combination with Wegovy called CagriSema. Lilly has an amylin drug in ...

At the forefront of the amylin push is Novo, which is advancing CagriSema, a combo regimen of its semaglutide, with the long-acting amylin drug cagrilintide. Late last year, however, the pharma ...

“The fourth quarter of 2024 was marked by two key announcements: the filing of patents covering, in particular, BioChaperone CagriSema—a stable combination of cagrilintide and semaglutide ...

compared to 82.5% for cagrilintide and 70.2% for semaglutide, the comparator drugs. Following the announcement, Novo Nordisk's stock price plunged nearly 18%, according to the lawsuit. The ...

Zealand Pharma is based in Denmark. Credit: Zealand Pharma via LinkedIn. Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement ...

Several short-term and long-term clinical trials have shown that the addition of pramlintide to preexisting insulin therapy improved postprandial and overall glycemic control (hemoglobin A 1c ...